How Does the Immune System Detects Cancer Cells?
6 月 16, 20261 Min Read What Is Tumor Immunology?
7 月 6, 2026Cancer cells aren't just randomly growing — they're actively learning how to make the immune system blind to them
—— Immune evasion: six survival strategies that tumors evolved.
I. Survivorship bias: tumors that grow are escape experts
This is the most important cognitive framework for understanding immune evasion. The immune system clears countless cancerous cells daily, but it's not only clearing — it's unknowingly conducting natural selection on the tumor cell population. Cells easily recognized and cleared died; cells that happened to acquire mutations making them harder to detect survived.
This is the essence of the 'Escape' phase in 'Immunoediting' theory: a cancer cell population capable of forming a clinically visible tumor is already the elite survivors of years of immune selection pressure. They didn't survive randomly — they happened to evolve the best immune evasion strategies. This perspective completely changes our understanding of tumors: tumor immune evasion capacity isn't a tumor's innate attribute, but a capacity evolved under immune system pressure.
2. PD-L1: the most important 'immune shutdown switch'
Among all immune evasion mechanisms, PD-L1 (Programmed Death-Ligand 1) is the most deeply researched and most widely applied clinically. PD-1 (Programmed Death receptor 1) is a receptor on T cell surfaces; its normal function is to 'brake' T cells after the immune response ends — preventing overactivated immune responses from damaging normal tissue. When a T cell's PD-1 binds to its ligand PD-L1, the T cell enters an 'exhausted' state: stops proliferating, stops releasing cytokines, stops killing.
Cancer cells discovered this mechanism and learned to exploit it. Many tumor cells (and macrophages co-opted by tumors) massively express PD-L1 on their surfaces. When tumor-specific T cells finally find the tumor and approach ready to attack, they find the tumor cell's surface PD-L1 binding to their own PD-1 — the brakes are fully applied, and the T cell is shut off at the last step before reaching its target.
This is why anti-PD-1 and anti-PD-L1 antibodies (Pembrolizumab, Nivolumab, Atezolizumab) produced such significant clinical results: they block PD-1/PD-L1 binding, removing the blockade on T cells, letting the previously trapped T cells reactivate and launch their attack.
3. MHC-I downregulation: blinding T cells while leaving a handle for NK cells
Many tumors downregulate MHC-I to evade T cell recognition — common in lung cancer, colorectal cancer, and melanoma. But MHC-I downregulation triggers NK cells' 'Missing Self' recognition. Tumor cells face a dilemma: keep MHC-I and T cells can see them; downregulate MHC-I and NK cells come after them.
Tumors evolved a clever solution — upregulating a non-classical MHC-I molecule called HLA-E. HLA-E can bind NK cells' inhibitory receptors (NKG2A), making NK cells think 'ID exists' and letting the tumor cell pass. Anti-NKG2A antibodies (Monalizumab) are specifically designed to block this evasion pathway, currently in clinical trials.
4. How tumors co-opt the immune system to become accomplices
The most shocking immune evasion mechanism isn't making the immune system 'blind' to the tumor — it's making the immune system actively help the tumor grow. In the tumor microenvironment, there's a cell type called tumor-associated macrophages (TAMs). Macrophages normally have two functional polarities: M1 (pro-inflammatory, kills tumors) and M2 (anti-inflammatory, promotes tissue repair). Tumors release specific signals (IL-4, IL-13, TGF-β, CSF-1, etc.) driving surrounding macrophages toward M2 polarization. M2 macrophages don't attack tumors — instead they secrete pro-angiogenic factors (VEGF), matrix metalloproteinases promoting tumor invasion, and suppress T cell and NK cell activity.
Similarly, Treg cells (regulatory T cells) in normal immunity are 'brakes' preventing immune over-activation. Tumors secrete chemokines attracting Treg cells into the tumor microenvironment, using them to suppress tumor-specific T cell activity. The tumor borrows weapons from the surrounding immune system to suppress resistance against itself.
5. TGF-β: the tumor's all-purpose immunosuppressive tool
Among all immunosuppressive factors tumors secrete, TGF-β (Transforming Growth Factor β) is the most widely used and most far-reaching. TGF-β in the tumor microenvironment is a multi-target immunosuppressive machine: directly suppresses NK cell activity (including downregulating NK cell surface activating receptors like NKG2D); suppresses CD8+ T cell proliferation and cytotoxic function; drives macrophages toward M2 polarization; promotes Treg cell development; suppresses dendritic cell maturation affecting tumor antigen presentation.
Almost every step of the immune system's anti-tumor process, TGF-β can interfere with. A 2018 Nature study (Mariathasan et al.) found that in bladder cancer patients, TGF-β not only suppresses immune cell function but physically traps T cells in fibrous tissue around the tumor, physically preventing them from entering the tumor core. Blocking TGF-β pathways combined with other immunotherapy could synergistically enhance anti-tumor effects; multiple combination therapies are in clinical trials.
6. Understanding evasion is the prerequisite for designing treatment
Every immune evasion mechanism is a potential treatment target. Cancer cells use PD-L1 to shut off T cells → use anti-PD-1/PD-L1 antibodies to re-open T cells. Cancer cells use HLA-E to suppress NK cells → research NKG2A inhibitors to remove NK cell blockade. Cancer cells downregulate MHC-I to hide from T cells → NK cell therapy has advantages with these tumors. Tumors co-opt macrophages → target CSF-1R to clear M2 macrophages, or re-polarize them to M1.
But reality is more complex than this 'one-to-one' logic. Mature tumors typically use multiple evasion mechanisms simultaneously; targeting one often only partially works, and tumors quickly escape through other pathways. This is why clinical treatment increasingly uses combination treatment strategies — simultaneously targeting multiple evasion pathways, sealing off the tumor's escape routes.
Frequently Asked Questions